News
INAB
--
0.00%
--
IN8bio to Present at Upcoming January Investor Conferences
NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced that Will...
GlobeNewswire · 01/10 12:00
IN8bio Announces Clinical Updates From The Phase 1 Clinical Trial Of Its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma Multiforme
INB-200 is the first-ever genetically modified gamma-delta T cell therapy in clinical trials and is currently in a repeated-dose escalation cohort Cohort 1 dosing is complete with three patients who received a
Benzinga · 01/06 12:06
IN8bio Stock Jumps After An Update From Leukemia Trial
IN8bio Inc (NASDAQ: INAB) has 
Benzinga · 12/16/2021 18:06
BRIEF-IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
reuters.com · 12/16/2021 12:15
IN8bio Provides Update From The Ongoing Phase 1 Clinical Trial Of Its Allogeneic Gamma-Delta T Cell Therapy In Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
  The ongoing Phase 1 trial of INB-100 is the first and most clinically advanced program administering large systemic doses of allogeneic gamma-delta T cells to patients   3 patients have been
Benzinga · 12/16/2021 12:08
In8bio promotes Kate Rochlin to COO
IN8bio (NASDAQ:INAB) announced the promotion of Kate Rochlin to COO. Rochlin previously served as VP, operations and innovation. Dr. Rochlin will be responsible for multiple functional areas, including chemistry, manufacturing
Seekingalpha · 12/10/2021 11:27
60 Biggest Movers From Yesterday
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 200.4% to close at $15.05 on Monday after the company announced the commencement of a formal process to explore strategic options to maximize shareholder value, including potential merger or acqui...
Benzinga · 12/07/2021 10:14
BRIEF-In8bio Posts Q3 Loss Per Share Of $0.25
reuters.com · 11/10/2021 23:08
IN8bio, Inc. - Common Stock Q3 EPS $(0.25) Up From $(0.60) YoY
IN8bio, Inc. - Common Stock (NASDAQ:INAB) reported quarterly losses of $(0.25) per share. This is a 58.33 percent increase over losses of $(0.60) per share from the same period last year.
Benzinga · 11/10/2021 22:29
IN8bio reports Q3 results
IN8bio (NASDAQ:INAB): Q3 GAAP EPS of -$0.25. Press Release.
Seekingalpha · 11/10/2021 22:13
IN8bio to Present at Scientific Conferences in November: PEGS Europe, SITC and SNO
NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, today announced presentat...
GlobeNewswire · 11/04/2021 12:00
Possible turnaround for IN8bio, Inc. (NASDAQ:INAB) insiders, still down US$241k after a US$1.0m shopping spree
Insiders who bought US$1.0m worth of IN8bio, Inc. ( NASDAQ:INAB ) stock in the last year recovered part of their losses...
Simply Wall St. · 11/01/2021 13:28
BRIEF-In8bio’S Announces Publication Of Preclinical Results In Mouse Models Of Glioblastoma Multiforme
reuters.com · 10/27/2021 12:44
20 Stocks Moving in Tuesday's Pre-Market Session
Gainers Communications Systems, Inc. (NASDAQ: JCS) rose 34.8% to $9.15 in pre-market trading as the company declared a special dividend of $3.50 per share.
Benzinga · 09/14/2021 11:13
5 Stocks To Watch For September 13, 2021
Some of the stocks that may grab investor focus today are: Wall Street expects Oracle Corporation (NYSE: ORCL) to report quarterly earnings at $0.97 per share on revenue of $9.77 billion after the closing bell. Oracle shares fell 0.1% to $89.64 in after-ho...
Benzinga · 09/13/2021 08:42
IN8bio reports Q2 results
IN8bio (NASDAQ:INAB): Q2 Net loss of $3.1M Cash position of $12M Press Release
Seekingalpha · 09/10/2021 20:26
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26)
Benzinga · 08/31/2021 12:05
IN8bio to Present at the NewYorkBIO Virtual Breakfast Series and H.C. Wainwright 23rd Annual Global Investment Conference
NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, today announced that Will...
GlobeNewswire · 08/30/2021 11:00
Mizuho Initiates Coverage On IN8bio with Buy Rating, Announces Price Target of $12
Mizuho analyst Mara Goldstein initiates coverage on IN8bio (NASDAQ:INAB) with a Buy rating and announces Price Target of $12.
Benzinga · 08/24/2021 13:43
--Mizuho Securities Starts IN8bio at Buy With $12 Price Target
MT Newswires · 08/24/2021 09:43
Webull provides a variety of real-time INAB stock news. You can receive the latest news about IN8BIO INC through multiple platforms. This information may help you make smarter investment decisions.
About INAB
IN8bio, Inc. is a clinical-stage biotechnology company. The Company is focused on and developing therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The Company's product candidate includes INB-200 and INB-100. INB-200 is genetically modified autologous gamma-delta T cell product candidate that the Company is developing for the treatment of solid tumors. Its indication for INB-200 is glioblastoma (GBM). INB-100 is its allogeneic product candidate that is developed for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation (HSCT). The Company is also developing a portfolio of preclinical programs. INB-400 is its preclinical program focused on developing allogeneic cellular therapies for solid tumor cancers and INB-300 is the preclinical program focused on developing product candidates based on gamma-delta T cells with an added chimeric antigen receptor (CAR).